Achieve Life Sciences Names Jaime Xinos New Chief Commercial Officer
Promoting Leadership at Achieve Life Sciences
Seattle and Vancouver—Achieve Life Sciences, Inc. (Nasdaq: ACHV), a pioneering late-stage pharmaceutical company, has made an important announcement regarding its leadership team. Ms. Jaime Xinos has been promoted to Chief Commercial Officer, immediately taking on this expanded role. This is a significant step as the company focuses on advancing its plans for cytisinicline, intended for those struggling with nicotine dependence.
Jaime Xinos: A Valuable Asset to Achieve Life Sciences
Since joining Achieve Life Sciences in 2017, Ms. Xinos has played a crucial part as the Executive Vice President of Commercial. In her new capacity, she will be responsible for all commercial operations, facilitating the strategic preparation for the upcoming U.S. launch of cytisinicline. This involves ensuring essential readiness among key stakeholders, including patients, healthcare providers, and payors, which is vital for a successful drug launch following FDA approval.
CEO's Remarks on Ms. Xinos's Promotion
Rick Stewart, the CEO of Achieve Life Sciences, expressed enthusiasm regarding the promotion of Jaime, highlighting her unwavering commitment to the company’s commercial strategies. He emphasized, “Her innovative, patient-first digital strategies are integral to achieving our goals of bringing cytisinicline to market.” Through her leadership, Stewart believes that the company can better facilitate drug readiness, making a significant difference for many individuals coping with smoking and vaping dependencies.
Driving Strategic Partnerships
Under her leadership, Ms. Xinos will also direct Achieve's efforts to establish partnerships with other firms and experts in commercialization. This collaborative strategy is essential, as it addresses the unique challenges faced by small biotech companies introducing their inaugural products. The aim is to offer innovative, value-driven solutions for smooth market entry and long-term success.
Ms. Xinos's Vision for Cytisinicline
In her own words, Xinos stated, “I’m honored to step into this expanded role as Chief Commercial Officer at such a pivotal time for Achieve Life Sciences.” She emphasized the immense potential of cytisinicline, aiming to be the first new FDA-approved treatment for nicotine dependence in almost twenty years. Xinos is determined to focus on cultivating strong collaborations while executing an innovative strategy to enhance patient care.
Experience and Expertise
Ms. Xinos brings a wealth of experience to her new role, boasting close to 25 years in the biotechnology and pharmaceutical sectors. Her background includes significant positions at prestigious organizations such as OncoGenex, Pfizer, Novartis, and Abbott Laboratories. Renowned for her ability to integrate scientific breakthroughs with robust business strategies, she has demonstrated exceptional prowess in developing products across various stages of their lifecycle. Ms. Xinos holds both a Bachelor of Arts and a Master of Business Administration from the University of Illinois, underscoring her solid foundation in education.
About Achieve Life Sciences and Cytisinicline
Achieve Life Sciences is dedicated to combating the global epidemic of smoking and nicotine addiction by advancing cytisinicline's development and commercialization. In the U.S. alone, there are about 29 million adults who still smoke combustible cigarettes. Tobacco use is a leading cause of preventable deaths, accounting for over eight million fatalities worldwide each year, alongside hundreds of thousands of deaths in the U.S.
Moreover, the increasing trend of e-cigarette usage among adults, with more than 11 million engaged in vaping, underscores the urgent need for effective cessation solutions. Cytisinicline emerges as a promising investigational drug candidate that may help combat nicotine addiction. As a plant-based alkaloid, it interacts with nicotinic receptors in the brain, potentially alleviating cravings and altering the reinforcement of nicotine.
Frequently Asked Questions
1. What is Achieve Life Sciences focusing on?
Achieve Life Sciences is concentrating on the development and commercialization of cytisinicline for treating nicotine dependence.
2. Who is the newly appointed Chief Commercial Officer?
Jaime Xinos has been appointed the Chief Commercial Officer of Achieve Life Sciences, promoted from her previous role as Executive Vice President of Commercial.
3. What is cytisinicline?
Cytisinicline is a plant-based alkaloid developed to help treat nicotine addiction, showing promise as an aid for smoking and vaping cessation.
4. How does Achieve Life Sciences plan to prepare for cytisinicline's launch?
The company aims to drive readiness by engaging with key stakeholders such as patients, healthcare providers, and payors to ensure a successful launch.
5. What experience does Jaime Xinos bring to her new role?
Ms. Xinos has nearly 25 years of experience in the biotechnology and pharmaceutical industries, with notable roles at leading companies such as Pfizer and Novartis.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Sterling Construction Achieves Record Stock Price of $160.99
- Cavco Industries Achieves Milestone with Record Stock Surge
- First Horizon Stock Surges to New Heights with Robust Growth
- CacheFly Enhances European Network with New Milan Presence
- CacheFly Expands Global Network with New Milan Point of Presence
- Alpine Power Systems Expands Capacity with New Facility
- Unlocking Potential with NOLAN: A New Era in Loan Analytics
- Silvercrest Metals Achieves 52-Week High Strengthening Market Position
- Fidelity National Information Services Achieves Stock Milestone
- DocuSign Achieves Major Milestone with Stock Surging Over 64%
Recent Articles
- AXON Networks Enhances Portfolio with DZS Software Acquisition
- Ribbon Communications Recognized for Sustainability Success
- Chatham Park Shines Bright with Awards at Esteemed Event
- Brink’s Company Preparing for Upcoming Earnings Call
- Prosperity Asset Management Welcomes New Leaders to Drive Growth
- Nykredit Realkredit Adjusts Coupon Rates for Floating Bonds
- Crombie REIT Announces Monthly Distribution for Investors
- Ladybug Nutratech Reports Impressive Sales Growth in 2024
- European Wax Center Rises in Franchise Times Rankings for 2024
- Exploring the Impact of Semiconductor News on Direxion ETFs
- OneRail's Bill Catania Celebrated as Top Entrepreneur by GS
- WOLFBOX Marks Five Years as a Leader in Automotive Tech
- Nevada King Gold Expands Exploration with Phase 3 Drill Plan
- CTAboi Aims to Simplify Beneficial Ownership Reporting for LLCs
- Progress at Libero Copper's Mocoa Project: Resource Expansion
- Chronograph Partners with Cambridge Associates for Enhanced Insights
- Outcrop Silver Expands Aguilar High-Grade Discoveries
- SOLTECH Achieves Women's Business Enterprise Certification
- REI Systems Lands Major Education Grant with GovGrants® Solution
- Axcelis Technologies Reveals Upcoming Q3 2024 Financial Results
- Blueprint Medicines To Reveal Q3 2024 Financial Insights Soon
- Acurx Pharmaceuticals Schedules Q3 2024 Conference Call
- Hyundai Mobis Expands Electrification with New European Facility
- Subway® Unveils Spicy Ghost Pepper Bread to Ignite Sandwiches
- Aetna Unveils SimplePay Health: Redefining Health Care for Users
- Iris Energy Accelerates Texas Data Center Energization Plans
- Baird Optimizes MasterCard Price Target Amidst Positive Growth
- Indaptus Therapeutics Remains Strong with Buy Rating and Updates
- Exelixis Celebrates Legal Win and Looks Toward Future Growth
- Albertsons Faces Challenges Amid Market Share Decline
- Uxin Joins Forces with Wuhan Economic Zone for Growth
- Morgan Stanley Reports Impressive 32% Increase in Profits
- Cautious Investors Slow Asian Bond Capital Inflows Amidst Uncertainty
- Morgan Stanley Surges on Strong Q3 Earnings Report
- Top High-Yield Stocks to Enhance Your Investment Strategy
- U.S. Bancorp Reports Impressive Earnings Amid Rising Rates
- Challenges Loom for Electric Vehicle Owners Amidst Depreciation
- Worksport Engages Investors in Insightful Chat with Analyst
- Torr Metals Advances Filion Gold Exploration with New Crews
- Text Request and Commify Join Forces to Enhance Messaging Solutions
- Exploring the Rapid Growth of the 3D Printing Medical Devices Market
- Exploring the Growth of the Global Identity Verification Market
- Global Breast Implants Market Growth to Reach $4.46 Billion
- Lee Shavel's New Role: A Vision for the Insurance Industry
- Chefs’ Warehouse to Reveal Third Quarter Financials Soon
- Northern Technologies International Corporation Declares Dividend
- Standard BioTools Prepares for Upcoming Financial Results Call
- Western Metallica Secures C$1 Million to Propel Copper Exploration
- Interfor Corporation Sells Québec Operations to Focus Growth
- Finov8r: Transforming Financial Advisory for Future Growth